Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,237.95 -728.44 (-1.14%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Eli Lilly and Company (LLY.DE)
| Previous close | 675.60 |
| Open | 679.70 |
| Bid | 687.70 x 0 |
| Ask | 688.60 x 0 |
| Day's range | 672.60 - 688.90 |
| 52-week range | 359.80 - 737.50 |
| Volume | |
| Avg. volume | 6,450 |
| Market cap | 654.983B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 128.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.75 (0.69%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
- PR Newswire
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
- PR Newswire
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
